2,5-Dihydro-2,5-Dioxo-1H-Pyrrole-1-Acetaldehyde

In the preparation of injectable matrix formulations for soft tissue repair, the aldehyde group of 2,5-Dihydro-2,5-Dioxo-1H-Pyrrole-1-Acetaldehyde undergoes rapid Schiff-base condensation with primary amine residues on gelatin (Type A, bloom 300) at pH 7.4 and 37 °C, while the maleimide ring provides a secondary, kinetically decoupled crosslinking mechanism. A twin-barrel syringe system equipped with a 2.5 mm static mixer tip delivers equal volumes of a 10% w/v gelatin solution pre-adjusted to pH 8.0 and a complementary solution containing 1.8 wt% thiolated hyaluronic acid (Thiol-HA, degree of substitution 45%) together with 0.6 wt% of the aldehyde-maleimide compound. Rheological gelation time, measured on a TA Instruments Discovery HR-20 rheometer with a 40 mm parallel-plate geometry at 1 Hz frequency and 1% strain amplitude, shifts from 18 ± 3 seconds to 42 ± 5 seconds when the maleimide-to-thiol molar ratio is decreased from 1.4:1 to 0.8:1. The aldehyde reacts within the first 5–8 seconds to establish a primary network that retards phase separation; subsequent maleimide-thiol addition proceeds with a half-life of approximately 6 minutes at pH 6.8 and 25 °C, allowing the surgeon sufficient working time before the cured hydrogel reaches a storage modulus G′ of 4.2 ± 0.7 kPa. Cytotoxicity evaluation follows ISO 10993-5:2009 using L929 murine fibroblasts with MTT assay readout at 570 nm; extracts prepared in MEM supplemented with 10% fetal bovine serum must maintain cell viability above 70% relative to blank controls. Bacterial endotoxin content is tested per USP <85> and controlled below 0.5 EU/mg. Process risks include premature aldehyde oxidation to the corresponding carboxylic acid during storage—pre-drying of the lyophilized compound over phosphorus pentoxide and packaging under argon at −20 °C are mandatory when ambient relative humidity exceeds 45%.

How Is the Aldehyde Functionality Exploited in Cleavable ADC Linker Design?

The molecule serves as a key intermediate in constructing enzyme-sensitive linker-drug platforms for antibody-drug conjugates (ADCs) that require a pH-labile hydrazone or an enzymatically cleavable peptide spacer. The maleimide ring undergoes Michael addition with a reduced interchain cysteine thiol on the monoclonal antibody (mAb) at a stoichiometric ratio of 1.15–1.25 moles of compound per mole of engineered cysteine, performed under nitrogen in 50 mM Tris-HCl buffer, pH 7.2, containing 5 mM EDTA to chelate trace metal ions. Unconjugated maleimide is quenched with 2 equivalents of L-cysteine and removed via tangential flow filtration (TFF) on a 30 kDa regenerated cellulose membrane. The aldehyde group is subsequently reacted with a drug-hydrazide derivative—such as monomethyl auristatin E (MMAE) linked through a hydrazine moiety—at pH 5.5 ± 0.1 in 100 mM sodium acetate buffer containing 10% v/v N,N-dimethylacetamide to maintain drug solubility. The hydrazone bond formation is monitored by analytical size-exclusion chromatography (SEC) on a TSKgel G3000SW_XL column with UV detection at 280 nm and 248 nm; residual free drug is quantified by reverse-phase HPLC and must not exceed 1.2 ppm per dose equivalent. Purification employs preparative SEC on a Sephacryl S-200 HR column, and the final drug-to-antibody ratio (DAR) is determined by hydrophobic interaction chromatography, typically maintained at 3.8–4.2. All steps are executed in a Class C cleanroom under compliance with ICH Q7 Good Manufacturing Practice for active pharmaceutical ingredients, and residual palladium from earlier coupling steps is controlled below 10 ppm per ICH Q3D Elemental Impurities Guideline. A primary operational boundary is the sensitivity of the aldehyde to air; all buffer preparations and conjugation reactions require de-oxygenation by argon sparging for minimum 30 minutes, and the free aldehyde intermediate must not be exposed to ambient atmosphere for longer than 15 minutes at room temperature to avoid irreversible oxidation.

A fluorescence-based protein detection workflow capitalizes on the dual reactivity to construct a horseradish peroxidase (HRP)–antibody reporter conjugate with a defined linker arm length. Rabbit anti-human IgG (F(ab′)₂ fragment) is first reduced with 10 mM 2-mercaptoethylamine in pH 6.0 MES buffer for 90 minutes at 37 °C to expose hinge-region sulfhydryls, then desalted on a HiTrap Desalting column pre-equilibrated with 20 mM MES, pH 6.5. The aldehyde-maleimide crosslinker is added at a 20:1 molar excess relative to free thiol content and incubated in the dark for 2 hours. After removal of excess crosslinker via spin filtration, the antibody intermediate carries pendant aldehyde groups. HRP previously modified with adipic acid dihydrazide (ADH) using EDC/NHS chemistry at pH 5.0 is introduced at a 5:1 HRP-to-antibody molar ratio; the aldehyde-hydrazide condensation proceeds at pH 5.5 overnight at 4 °C and is stabilized by reduction with 50 mM sodium cyanoborohydride. The resulting conjugate is purified on a Superdex 200 Increase 10/300 GL column, and conjugate integrity is verified by SDS-PAGE under non-reducing conditions with silver staining, comparing bands to low-range molecular weight markers (10–260 kDa). Functionality is assessed by direct ELISA against coated human IgG antigen, following CLSI EP5-A2 for intra-assay precision across 20 replicates; coefficients of variation at 1 ng/mL antigen concentration must remain under 7%. Batch records must demonstrate compliance with USP <467> residual solvent limits for N,N-dimethylformamide (880 ppm) if used in earlier synthesis steps. Published data for this specific configuration is limited; however, analogous heterobifunctional aldehyde-maleimide PEG crosslinkers report a conjugation yield of >85% with maintained enzymatic activity within ±10% of unmodified HRP, and the same performance acceptance window is provisionally applied. The key failure mode observed in pilot runs is over-reduction of the antibody leading to hinge fragmentation—reaction time and temperature must be controlled within a narrow window of 85–95 minutes and 36.5–37.5 °C.

When 2,5-Dihydro-2,5-Dioxo-1H-Pyrrole-1-Acetaldehyde Is Copolymerized with Styrene via Free-Radical Initiation

The monomer is incorporated into styrene bulk polymerization to produce a linear poly(styrene-co-maleimide aldehyde) that can later be functionalized for affinity chromatography media. A feed ratio of 1.5 mol% aldehyde-maleimide comonomer and 0.3 mol% azobisisobutyronitrile (AIBN) relative to total monomer is dissolved in anhydrous methyl ethyl ketone at 30% w/v solids. The solution is sparged with nitrogen for 45 minutes, then heated to 70 °C for 24 hours under a nitrogen blanket with gentle overhead stirring. The resulting polymer is precipitated into a tenfold excess of cold methanol, filtered, and dried under vacuum at 40 °C for 48 hours. Gel permeation chromatography against polystyrene standards (THF, 1 mL/min) yields a number-average molecular weight Mn of 48,000–55,000 Da with a polydispersity of 1.8–2.1. Aldehyde content is quantified by titration with hydroxylamine hydrochloride and back-titration with sodium hydroxide using a Metrohm 888 Titrando. The copolymer is deposited onto crosslinked agarose beads (Sepharose CL-6B) by solvent evaporation from dichloromethane suspension to yield a pre-activated chromatography resin bearing accessible maleimide and aldehyde groups; subsequent immobilization of peptide ligands via N-terminal cysteine proceeds at pH 6.8 in 0.1 M phosphate buffer with ligand densities up to 12 μmol/mL gel. Residual styrene monomer in the final resin is determined by headspace GC-MS according to ASTM D4526-20 and must be below 85 ppm for biologic feedstock use. A critical process restriction is that the maleimide ring partially undergoes retro-Diels-Alder degradation above 110 °C during any post-polymerization heat treatment; therefore, all drying and column packing steps must be conducted below 50 °C. Amine-containing buffers must be strictly avoided during resin activation, as they would consume the aldehyde and render the support inactive.

An intermediate strategy for constructing biotin-streptavidin pull-down probes exploits the orthogonal groups on the molecule without resorting to pre-functionalized agarose supports. Biotin hydrazide is prepared by reacting biotin N-hydroxysuccinimide ester with hydrazine monohydrate in dimethyl sulfoxide at 25 °C for 12 hours and is purified by silica gel chromatography. The aldehyde-maleimide building block is first conjugated to a model protein—such as recombinant green fluorescent protein (GFP) containing a single surface-exposed cysteine—by maleimide-thiol chemistry in 50 mM HEPES, pH 7.0, at 4 °C for 3 hours. Excess reagent is removed by centrifugal filtration with a 10 kDa cutoff. In a second step, the biotin hydrazide is added at 2.5× molar excess relative to protein-aldehyde groups and incubated at pH 5.2 (100 mM sodium citrate) for 16 hours at 4 °C to form a stable hydrazone. The dual-labeled protein is dialyzed against PBS and its biotin content verified by HABA-avidin assay; typical substitution ratios range from 0.7 to 1.1 biotin molecules per protein. Pull-down efficiency tested with streptavidin magnetic beads (Dynabeads M-280) under gentle rotation for 45 minutes exceeds 80% recovery as assessed by fluorescence intensity of the supernatant at 509 nm. Documentation for in-vitro diagnostic component manufacturing under ISO 13485:2016 requires traceability of the aldehyde-maleimide batch to raw material purity logs, with HPLC purity >97% area at 210 nm. The aldehyde midpoint potential is sensitive to ambient humidity; operators report that processing after opening the container at relative humidity exceeding 60% without immediate reseal leads to a measurable loss of aldehyde activity (5–10% decrease within 30 minutes), as confirmed by FTIR monitoring of carbonyl stretching at 1724 cm⁻¹.

What Optimized Procedure Governs Oriented Antibody Immobilization on Gold-Coated SPR Chips?

Surface plasmon resonance sensor chip functionalization with oriented capture antibodies is achieved by forming a mixed self-assembled monolayer (SAM) on a bare gold sensor (Biacore Au Chip) that incorporates the aldehyde-maleimide compound as a heterocrosslinker. The gold surface is cleaned in piranha solution and rinsed with ultrapure water (18.2 MΩ·cm), then immediately immersed in a 0.2 mM ethanolic solution of an amine-terminated alkanethiol (11-amino-1-undecanethiol) together with 0.02 mM of the aldehyde-maleimide compound for 16 hours at room temperature in the dark. The terminal amine groups on the SAM are subsequently activated with a 10 mM solution of disuccinimidyl carbonate in acetonitrile for 2 hours, enabling the covalent attachment of the aldehyde-maleimide spacer via amide bond formation. After rinsing, a solution of F(ab′)₂ fragment of the target antibody, previously reduced with 5 mM TCEP in 20 mM acetate buffer pH 5.0 to expose hinge-region thiols, is injected over the chip for 12 minutes at a flow rate of 5 μL/min. The maleimide-thiol coupling is monitored in real time, with typical immobilization levels of 3800–4200 RU achieved on a Biacore T200 instrument. Residual reactive maleimide groups are deactivated with a 1.0 M ethanolamine-HCl solution at pH 8.5 injected for 7 minutes. The aldehyde moieties that remain free on the surface can later be coupled to carbohydrate chains of glycoprotein analytes after periodate oxidation, providing an additional orthogonal capture mechanism. Data acquisition complies with 21 CFR Part 11 electronic record regulations, and instrument qualification follows the manufacturer’s IQ/OQ protocol. Baseline drift is maintained below 0.3 RU/min by thermostating the chip compartment at 25.00 ± 0.05 °C. The primary limitation is the relatively short shelf life of the maleimide group under aqueous conditions; the functionalized chip must be used within 48 hours if stored in degassed PBS at 4 °C to avoid ring hydrolysis that converts maleimide to unreactive maleamic acid, which is confirmed by the appearance of a new 1640 cm⁻¹ band in PM-IRRAS spectra.